SOUTH SAN FRANCISCO, Calif., May 30 /PRNewswire-FirstCall/ --
Corgentech Inc. (Nasdaq: CGTK) today announced the appointment of Susan
Kramer, Dr.P.H. as vice president of preclinical development.
"Susan's more than 20 years of leading research, preclinical and
clinical development programs will be instrumental in providing robust
support for our future clinical programs and advancement of pain products
into our development pipeline," said John P. McLaughlin, chief executive
officer of Corgentech.
Dr. Kramer joins Corgentech from BAS Medical, where she was a
co-founder and served as vice president of research and development from
2003 to 2006. She was instrumental in the initiation of the company's
preclinical and clinical programs. Prior to BAS Medical, Dr. Kramer worked
at Genentech for 18 years in a number of roles of increasing management
responsibility, including director of product development, senior director
of bioanalytical technology and ultimately as senior director of
development sciences operations and strategic planning. She served as
project team leader for products Actimmune(R) and Raptiva(R). She led
numerous pharmacology teams and served on several key committees, including
the Product Development Committee.
Prior to Genentech, Dr. Kramer served as the director of Medical
Laboratories in Montes Claros, Minas Gerais, Brazil as a Peace Corps
Volunteer, followed by a stint as head of the clinical virology laboratory
at the UCSF Medical Center at the onset of the AIDS epidemic. Dr. Kramer
holds Dr.P.H. and M.P.H. degrees in Biomedical Sciences from the University
of California, Berkeley.
Corgentech is a late-stage biopharmaceutical company that seeks to be
the leader in the development and commercialization of novel therapeutic
treatments for pain. The company has four drug candidates in clinical
development for multiple potential indications, the most advanced of which,
3268, has completed Phase 3 clinical trials. To reflect the company's core
focus on novel pain management therapies, the board of directors recently
voted to change the company name to Anesiva. If approved by stockholders at
the annual meeting on June 21, 2006, the name change will become effective
immediately thereafter. Corgentech is based in South San Francisco, CA.
Forward Looking Statements
This press release includes "forward-looking statements" within the
meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. Words such as "expect,"
"estimate," "project," "budget," "forecast," "anticipate," "intend,"
"plan," "may," "will," "could," "should," "believes," "predicts,"
"potential," "continue," and similar expressions are intended to identify
such forward-looking statements. Forward-looking statements in this press
release include, without limitation, projected timing of clinical
development and other matters that involve known and unknown risks,
uncertainties and other factors that may cause actual results, levels of
activity, performance or achievements to differ materially from results
expressed or implied by this press release. Such risk factors include,
among others: whether Corgentech can successfully develop new products and
the degree to which these gain market acceptance. Actual results may differ
materially from those contained in the forward-looking statements in this
press release. Additional information concerning these and other risk
factors is contained in Corgentech's quarterly report on Form 10-Q for the
quarter ended March 31, 2006.
Corgentech undertakes no obligation and does not intend to update these
forward-looking statements to reflect events or circumstances occurring
after this press release. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date of this
press release. All forward-looking statements are qualified in their
entirety by this cautionary statement.
SOURCE Corgentech Inc.